Polymorphisms in many xenobiotic metabolizing enzymes occur leading to variation in the level of enzyme expression in vivo. Enzymes showing such polymorphisms include the cytochrome P450 enzymes CYPlAl, CYP1A2, CYP2A6, CYP2D6, and CYP2E1 and the phase two metabolism enzymes glutathione S-transferase Ml (GSTMI) and arylamine N-acetyltransferase 2 (NAT2). In the past, these polymorphisms have been studied by phenotyping using in vivo administration of probe drugs. However, the mutations which give rise to several of these polymorphisms have now been identified and genotyping assays for polymorphisms in CYPIA 1, CYP2A6, CYP2D6, CYP2E1, GSTMI, and NAT2 have been developed. Specific phenotypes for several of the polymorphic enzymes have been associated with increased susceptibility to malignancy, particularly lung and bladder cancer, and Parkinson's disease. These associations are likely to be due to altered activation or detoxication of chemicals initiating these diseases, including components of tobacco smoke and neurotoxins. The substrate specificity and tissue distribution of polymorphic enzymes implicated in disease causation discussed with particular reference to previously described disease-phenotype associations
Introduction
There is considerable variation in expression of xenobiotic-metabolizing enzymes in the general population. This variability is due, at least in part, to the presence of genetic polymorphisms where mutations in the wild-type gene result in the synthesis of enzymes with impaired activity. Individuals expressing one or more of these mutated enzymes may differ from normal individuals in their susceptibility to certain diseases where exposure to xenobiotics is a possible cause. There is now clear evidence at the metabolic level for polymorphisms in the cytochrome P450 enzymes CYPlA1, CYP1A2, CYP2A6 and CYP2D6 and in Nacetyltransferase 2 (NAT2) and glutathione S-transferase MI (GSTMI) which carry out phase 2 conjugation reactions. In the case of CYP2D6, NAT2, and GSTMI, the genetic basis of the polymorphism is also well understood. There is also evidence at the genetic level for a polymorphism in the enzyme CYP2E1. As summarized in Table  1 , simple genotyping assays have been developed for a number of these polymorphisms. Associations between specific phenotypes for certain polymorphic enzymes and susceptibility to cancer, particularly lung and bladder cancer, Parkinson's disease, and the autoimmune disease systemic lupus erythematosus have been described. These associations may be due to differences in the ability of the various enzyme phenotypes to activate or detoxicate chemical toxins or, alternatively, to linkage disequilibrium where a particular allele coding for another gene with a direct role in determining disease susceptibility shows genetic linkage with an allelic variant of the xenobiotic-metabolizing enzyme.
This article considers associations between particular metabolic phenotypes and disease susceptibility, with particular emphasis on methods for determining genotypes. The relevance of the enzyme polymorphism-disease associations from what is known regarding substrates and tissue-specific expression is also considered.
However, it should be noted that metabolism at the site of the tumor may not be essential because many carcinogens may migrate to other tissues following metabolism in the liver (1 (3) . In two studies, the high inducibility phenotype was found to be more common among lung cancer patients than in a group of smoking controls (3, 4) . However, other workers (5-7) have failed to reproduce these findings.
Association of a CYPlAl genotype detectable by restriction fragment length polymorphism (RFLP) analysis using the enzyme MspI with increased susceptibility to lung cancer, particularly squamous cell carcinoma, among smokers has been reported for a Japanese population (8) . However, no such association was detected in a similar study of a Norwegian population (9 CYP2A6 is a constitutive cytochrome P450 which is expressed in human liver at variable levels (18) . This enzyme may also be expressed in other tissues, including nasal tissue (19) . CYP2A6 carries out 7-hydroxylation of coumarin but also appears to activate certain procarcinogens, including hexamethylphosphoramide (19) , Nnitrosodimethylamine (20) , NNK (14) and aflatoxin B1 (21) . Using coumarin as a probe drug, the formation of 7-hydroxycoumarin has been investigated in a group of volunteers. Considerable variation in the percentage of drug excreted as 7-hydroxy metabolites has been observed with levels of conversion varying from 10 to 120% of the dose (22 in rat tissues have demonstrated readily detectable levels of RNA expression in liver and kidney (28) . Expression has also been detected in human brain by PCR analysis of a caudate nucleus cDNA library (29) . Using poly A+ RNA from rat liver and lung, we have recently detected transcripts which hybridize to a CYP2D6 cDNA probe in both tissues (Figure 1 ). However, the major band approximately 8S in liver is at least 100-fold more intense than the corresponding band in lung. Two other higher molecular weight transcripts are also detected in liver but the larger and stronger of these is not detected in lung. (31) (32) (33) . The remaining 5% of PMs are likely to have rare mutations in one or both alleles. In a sequencing study on DNA from a subject classified phenotypically as a PM but with an apparent heterozygous genotype, we have detected a single base substitution (G2064 to A) in exon 4 of CYP2D6 which results in substitution of Glu for Gly. Using allele-specific PCR, approximately 100 subjects have been screened for the presence of this mutation; but in addition to the original subject studied, the mutation has only been detected in one other individual (also a PM), giving an allele frequency of 0.01.
In the past, phenotyping studies using debrisoquine or another CYP2D6-specific probe drug have suggested associations between particular phenotypes and disease susceptibility. As discussed above, there is evidence that CYP2D6 may activate the procarcinogen NNK while detoxicating certain neurotoxins. These findings as well as increasing evidence for extrahepatic expression of CYP2D6 may account for these phenotype-disease assocations. Two independent studies of lung cancer patients have demonstrated a reduced frequency of PMs and a generally increased level of metabolism of debrisoquine compared with several types of control group (34, 35) . Similarly, among cases of aggressive bladder cancer, a reduced frequency of the PM phenotype was observed (36) . A study of Parkinson's disease patients observed an increased frequency of PMs compared with controls (37) , although some of these findings were later ascribed to interference by other drugs in the debrisoquine phenotyping procedure (38) . An increased frequency of the autoimmune disease systemic lupus erythematosus among poor metabolizers has also been reported (39 Parkinson's disease patients and 72 controls. A small but not statistically significant increase was observed in the percentage of heterozygous extensive metabolizers but when allele frequencies between the two groups were compared, the CYP2D6B allele frequency was increased from 10.4% in the control group to 21.65% among cases, representing a relative risk of 2.7 (40) . These findings could be explained by linkage disequilibrium with an association between CYP2D6B and an allele from another gene with a role in determining susceptibility to this disease. In a study of a larger population (41) , an increase in frequency of the PM genotype from 5.0 to 11.8% was observed with a relative risk of 2.54. There is a need for further studies of this type, particularly to investigate the possibility that it may be early-onset Parkinson's disease in particular that is associated with the PM phenotype due to the role of CYP2D6 in the metabolism of neurotoxins.
A study on the relationship between CYP2D6 genotype and susceptibility to a number of different types of cancer has recently been reported (42) . In this study, CYP2D6B allele distributions for 1635 cancer patients and an unmatched control group of 720 random volunteers were examined. No significant difference in the frequency of the CYP2D6B allele between lung cancer patients and controls was observed. Some statistically significant differences in genotype frequencies between patients and controls were obtained for other tumors, including an increase in the percentage of PMs among leukemia patients. Although interesting, this study is very preliminary and there is a need to carry out well-designed case-control studies using genotyping methods which detect a higher percentage of PMs and heterozygotes and are validated by preliminary metabolic phenotyping of the study population. Definitive answers on the role of polymorphism in CYP2D6 in determining disease susceptibility should soon be available. CYP2E1 CYP2E1 metabolizes nitrosamines, including the procarcinogens N-nitrosodimethylamine and N-nitrosopyrrolidine (43), the tobacco smoke component 3-hydroxypyridine (44) and many common organic solvents including benzene (43 occur (45) . Expression has also been detected in rat lung (46) , rabbit nasal tissue and kidney (47) , and human leucocyte (48) .
A polymorphism in intron 2 of the human CYP2EJ gene is detectable by RFLP analysis with DraL. Genotyping analysis of a lung cancer patient group showed a significantly reduced incidence of a rare genotype among cases compared with a control group (49) . Two linked polymorphisms in the 5'-flanking region of CYP2EI affecting levels of transcription have also been identified (50) . PCR assays for analysis of these polymorphisms have been described but have not yet been applied to studies on disease susceptibility.
Glutathione S-Transferase p
Glutathione S-transferases are a multigene family of enzymes which conjugate xenobiotics with glutathione (51) . In the case of the near-neutral family, a polymorphism has been detected at the human GSTI locus which codes for glutathione S-transferase (GSTMI). Three different allelic variants have been detected, with two of these, GSTMI*A and GSTMI*B, coding for enzymes of similar catalytic activity (52) whereas GSTMI 0 (the null allele) produces no catalytically active enzyme and may represent complete deletion of the coding gene (53) . In most racial groups, 40 to 50% of subjects are homozygous for the null allele and lack GSTM (54) . GSTMI is expressed in a variety of human tissues including liver, leucocyte, kidney, and stomach (55) . Expression has also been detected in lung but this enzyme appeared to have a faster mobility than the liver form in Western immunoblot experiments and did not appear polymorphic (56) . Substrates for GSTMI include trans-stilbene oxide and benzo[a]pyrene-4,5-oxide (51) . GSTMI phenotyping can be carried out in leukocytes by assay for enzyme activity towards trans-stilbene oxide (57) or by immunoassay (58) . More recently, genotyping assays have been developed using either RFLP analysis with EcoRI or BamHI (53) or PCR assays (59) where absence of GSTMI amplification indicates that the subject is homozygous for the null allele.
Phenotyping studies on lung cancer patients have indicated that lack of GSTMI activity is associated with an increased risk of lung cancer-particularly adenocarcinoma-development among smokers (57) . More recently using both genotyping by RFLP analysis and phenotyping by radioimmunoassay, no significant difference in GSTMI expression was detected between a lung cancer group and a control group but a small but statistically significant increase in lack of GSTMI expression was seen among a subgroup of patients with squamous carcinoma (60) . In a recent case-control study on smoking-related cancers (mainly lung cancers) using phenotyping by enzyme activity measurements, there was no overall difference in the percentage of subjects with low levels of enzyme activity (GSTMI negative) between cancer patients and controls but a small increase in the percentage of GSTMI-negative subjects was detected in a subgroup of heavy smokers with smoking-related cancers (61) . At present, therefore the relationship between GSTMI expression and lung cancer susceptibility remains unclear. Aylarie N-Aceltransferase 2 Two forms of N-acetyltransferase (NAT1 and NAT2) carry out N-acetylation of arylamines and certain other reactions such as aacetylation (62) . Expression of NAT2 is polymorphic and about 50% of Caucasians lack this enzyme activity and are termed slow acetylators (63) . In addition to metabolizing a group of therapeutically important drugs, NAT2 also acetylates arylamines including benzidine, 2-aminofluorine and I-naphthylamine (16) . NAT has been detected in human liver (62) and colon (64) . In rabbits, NATis expressed in a variety of tissues including duodenum, lung, kidney, and bladder mucosa (63) .
Slow acetylators are detectable by phenotyping with a number of probe drugs including caffeine and sulphamethazine (63) . Recently, the NAT2 gene has been cloned and sequenced and a number of point mutations associated with the slow acetylator phenotype identified. Three variant alleles (Table 1) which lack NAT activity in vitro have been identified in several independent studies (65) (66) (67) (68) . Each variant contains one or more base substitutions with at least one of these introducing an amino acid change. The presence of the variant alleles can be readily detected by PCR assays using either digestion of product with a restriction enzyme or allele-specific methods (66, 67) , allowing positive identification of greater than 90% of all slow acetylators.
The association between acetylation phenotype and disease susceptibility has received considerable attention. Slow acetylators appear to be at increased risk for development of systemic lupus erythematosus if given certain NAT2 substrates therapeutically (63) . In addition, susceptibility to certain types of cancer involving chemical carcinogenesis may be related to acetylator phenotype. The majority of bladder cancer is likely to be related to either occupational exposure or cigarette smoking (69) . In a case-control study of occupationally induced bladder cancer, a large excess of slow acetylators was detected in the occupationally exposed group and an odds ratio of 16.7 calculated for risk of disease development in slow acetylators (70) . However, this study found no relationship between acetylator phenotype and development of smoking-related bladder cancer in the absence of confirmed occupational exposure to arylamines and subsequent independent studies have generally confirmed these findings (71) (72) (73) .
Trace amounts of arylamines may be formed during normal cooking of food. Since these compounds are likely NAT substrates, the possibility that acetylator phenotype might relate to susceptibility to colon cancer was investigated (74, 75 ). An increased frequency of the rapid acetylator phenotype was observed among a group of colorectal cancer patients. The difference in relationship between acetylator phenotype and susceptibility to bladder and colon cancer may be due to NAT primarily acting as a detoxicating enzyme in bladder while in the colon, N-oxidized arylamines may undergo activation by N-and 0-acetylation reactions catalyzed by NAT (16 
